125 related articles for article (PubMed ID: 32940080)
1. Galectin-3 and acute heart failure: genetic polymorphisms, plasma level, myocardial fibrosis and 1-year outcomes.
Fu H; Nie S; Luo P; Ruan Y; Zhang Z; Miao H; Li X; Wen S; Bai R
Biomark Med; 2020 Jul; 14(11):943-954. PubMed ID: 32940080
[No Abstract] [Full Text] [Related]
2. Genetic variants in
Cunha EGC; de Lima CAD; Vilar KM; Nóbrega MF; Almeida AR; Pereira MC; Dantas AT; Gonçalves RSG; Rêgo MJBM; Duarte ALBP; Pitta MGDR
Autoimmunity; 2021 Jun; 54(4):187-194. PubMed ID: 33973825
[TBL] [Abstract][Full Text] [Related]
3. Genetic determinants of circulating galectin-3 levels in patients with coronary artery disease.
Liao YH; Teng MS; Juang JJ; Chiang FT; Er LK; Wu S; Ko YL
Mol Genet Genomic Med; 2020 Sep; 8(9):e1370. PubMed ID: 32573962
[TBL] [Abstract][Full Text] [Related]
4. Influence of LGALS3 gene polymorphisms on susceptibility and prognosis of dilated cardiomyopathy in a Northern Han Chinese population.
Zhang Y; Wang Y; Zhai M; Gan T; Zhao X; Zhang R; An T; Huang Y; Zhou Q; Zhang J
Gene; 2018 Feb; 642():293-298. PubMed ID: 29129812
[TBL] [Abstract][Full Text] [Related]
5. Assessment of Galectin-3 Polymorphism in Subjects with Chronic Chagas Disease.
Cruz Gda S; Angelo AL; Larocca TF; Macedo CT; Noya-Rabelo M; Correia LC; Torreão JA; Souza BS; Santos RR; Soares MB
Arq Bras Cardiol; 2015 Nov; 105(5):472-8. PubMed ID: 26312551
[TBL] [Abstract][Full Text] [Related]
6. Influence of LGALS3 and PNPLA3 genes in non-alcoholic steatohepatitis (NASH) in patients undergone bariatric surgery.
Azevedo Foinquinos G; Azevedo Acioli ME; Santana Cavalcanti AH; Barbosa Junior WL; Lima RE; Juca NT; de Azevedo Foinquinos RC; Rocha da Cruz C; Fernandez Pereira FM; de Carvalho SR; de Mendonça Belmont TF; Vasconcelos LRS; Beltrão Pereira LMM
Obes Res Clin Pract; 2020; 14(4):326-332. PubMed ID: 32690320
[TBL] [Abstract][Full Text] [Related]
7. Plasma and Cardiac Galectin-3 in Patients With Heart Failure Reflects Both Inflammation and Fibrosis: Implications for Its Use as a Biomarker.
Besler C; Lang D; Urban D; Rommel KP; von Roeder M; Fengler K; Blazek S; Kandolf R; Klingel K; Thiele H; Linke A; Schuler G; Adams V; Lurz P
Circ Heart Fail; 2017 Mar; 10(3):. PubMed ID: 28288987
[TBL] [Abstract][Full Text] [Related]
8. Galectin-3 and histological, molecular and biochemical aspects of myocardial fibrosis in heart failure of hypertensive origin.
López B; González A; Querejeta R; Zubillaga E; Larman M; Díez J
Eur J Heart Fail; 2015 Apr; 17(4):385-92. PubMed ID: 25684565
[TBL] [Abstract][Full Text] [Related]
9. sST2 and Galectin-3 genotyping in patients with persistent atrial fibrillation.
Saez-Maleta R; Merino-Merino A; Gundin-Menendez S; Salgado-Aranda R; AlKassam-Martinez D; Pascual-Tejerina V; Martin-Gonzalez J; Garcia-Fernandez J; Perez-Rivera JA
Mol Biol Rep; 2021 Feb; 48(2):1601-1606. PubMed ID: 33486675
[TBL] [Abstract][Full Text] [Related]
10. Galectin 3 (
Kovacevic Z; Lazarevic T; Maksimovic N; Grk M; Volarevic V; Gazdic Jankovic M; Djukic S; Janicijevic K; Miletic Kovacevic M; Ljujic B
J Clin Med; 2022 Jul; 11(13):. PubMed ID: 35807161
[TBL] [Abstract][Full Text] [Related]
11. sST2 adds to the prognostic value of Gal-3 and BNP in chronic heart failure.
Barutaut M; Fournier P; Peacock WF; Evaristi MF; Dambrin C; Caubère C; Koukoui F; Galinier M; Smih F; Rouet P
Acta Cardiol; 2020 Dec; 75(8):739-747. PubMed ID: 31560863
[No Abstract] [Full Text] [Related]
12. Galectin-3 in Cardiovascular Diseases.
Blanda V; Bracale UM; Di Taranto MD; Fortunato G
Int J Mol Sci; 2020 Dec; 21(23):. PubMed ID: 33287402
[TBL] [Abstract][Full Text] [Related]
13. Prognosis value of galectin-3 in patients with dilated cardiomyopathy: a meta-analysis.
Xiong Y; Zhang Q
PeerJ; 2024; 12():e17201. PubMed ID: 38680895
[TBL] [Abstract][Full Text] [Related]
14. Evolution of the slopes of ST2 and galectin-3 during marathon and ultratrail running compared to a control group.
Le Goff C; Kaux JF; Farre Segura J; Stojkovic V; Ancion A; Seidel L; Lancellotti P; Cavalier E
Clin Chem Lab Med; 2020 Jan; 58(2):314-321. PubMed ID: 31622239
[TBL] [Abstract][Full Text] [Related]
15. Galectin-3 in Predicting Mortality of Heart Failure: A Systematic Review and Meta-Analysis.
Wu C; Lv Z; Li X; Zhou X; Mao W; Zhu M
Heart Surg Forum; 2021 Mar; 24(2):E327-E332. PubMed ID: 33798049
[TBL] [Abstract][Full Text] [Related]
16. A genome-wide association study of circulating galectin-3.
de Boer RA; Verweij N; van Veldhuisen DJ; Westra HJ; Bakker SJ; Gansevoort RT; Muller Kobold AC; van Gilst WH; Franke L; Mateo Leach I; van der Harst P
PLoS One; 2012; 7(10):e47385. PubMed ID: 23056639
[TBL] [Abstract][Full Text] [Related]
17. Circulating Galectin-3 Levels Are Persistently Elevated After Heart Transplantation and Are Associated With Renal Dysfunction.
Grupper A; Nativi-Nicolau J; Maleszewski JJ; Geske JR; Kremers WK; Edwards BS; Kushwaha SS; Pereira NL
JACC Heart Fail; 2016 Nov; 4(11):847-856. PubMed ID: 27614937
[TBL] [Abstract][Full Text] [Related]
18. Circulating galectin-3 on admission and prognosis in acute heart failure patients: a meta-analysis.
Chen H; Chen C; Fang J; Wang R; Nie W
Heart Fail Rev; 2020 Mar; 25(2):331-341. PubMed ID: 31641977
[TBL] [Abstract][Full Text] [Related]
19. Galectin-3 is a marker of myocardial and vascular fibrosis in Kawasaki disease patients with giant aneurysms.
Numano F; Shimizu C; Jimenez-Fernandez S; Vejar M; Oharaseki T; Takahashi K; Salgado A; Tremoulet AH; Gordon JB; Burns JC; Daniels LB
Int J Cardiol; 2015 Dec; 201():429-37. PubMed ID: 26313861
[TBL] [Abstract][Full Text] [Related]
20. Estimating systemic fibrosis by combining galectin-3 and ST2 provides powerful risk stratification value for patients after acute decompensated heart failure.
Wang CH; Yang NI; Liu MH; Hsu KH; Kuo LT
Cardiol J; 2016; 23(5):563-572. PubMed ID: 27515479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
